ΑΝΑΣΤΟΛΕΙΣ ΤΥΠΟΥ "ΑΝΤΙΠΡΟΘΡΟΜΒΙΝΑΣΗ". ΚΛΙΝΙΚΟΕΡΓΑΣΤΗΡΙΑΚΗ ΜΕΛΕΤΗ
THE LUPUS ANTICOAGULANT WAS DETECTED IN THE PLASMA OF 44 ADULTS DURING A 6-YEAR-PERIOD AT THE CENTRAL LABORATORY OF HEMOSTASIS IN THE HOSPITAL HENRI MENDER (FRANCE). THE CONSIDERABLE NUMBER OF PATIENTS AND THEIR NON-SELECTIVE RECRUITEMENT HAS PERMITTED TO DRAW VALUABLE CONCLUSIONS FROM CAREFUL STATISTICAL ANALYSIS OF CLINICAL AND LABORATORY DATA. THE MEAN DURATION OF FOLLOW-UP WAS 14 MONTHS AND EACH PATIENT WAS SUBJECTED TO COAGULATION TESTS 1 TO 12 TIMES (MEAN 3,16+2,4). OUR RESULTS DEMONSTRATE CLEARLY THE HIGH INCIDENCE OF THIS INHIBITOR AMONG PATIENTS WITHOUT SLE WHO ON THE OTHER HAND, PRESENT POSITIVE ANTINUCLEAR ANTIBODIES TESTS, LOW COMPLEMENT VALUES AND HIGH ESR. THE RELATION OF THIS ANTICOAGULANT TO DRUG INTAKE, THE ASSOCIATION OR DISSOCIATION TO THROMBOPENIA, BFP-STΓ, THROMBOSIS SPONTANEOUS FETAL WASTE AND OTHER OBSTETRICAL COMPLICATIONS ARE ANALYZED AND DISCUSSED AS WELL AS THE EVOLUTION OF THE INHIBITOR IN TIME AND THE INFLUENCE OF THERAPEUTIC MEASURES. OUR RESULTS PROVE THAT THE LUPUS ANTICOAGULANT IS "INNOCENT" SO FAR AS BLEED MANIFESTATIONS, PROLONGATION OF THROMBIN TIME AND DECREASE IN THE LEVEL OF FACTOR II ARE CONCERNED. BESIDES USEFUL PATHOGENIC CLUES, SPECIAL ASPECTS OF THE COAGULATION PROFILE ARE ANALYZED AND DISCUSSED, SUCHAS THE "COFACTOR" EFFECT, THE INTERFERENCE OF THE INHIBITOR IN THE ONE-STAGE MEASUREMENT OF THE FACTORS VIII, IX, XI, XII ETC .
ΑΝΤΙΠΡΟΘΡΟΜΒΙΝΑΣΗ, Αντιπυρηνικά αντισώματα, ΕΠΙΚΤΗΤΟΙ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΠΗΞΗΣ, Επιπλοκές κύησης, Θρομβώσεις, ΨΕΥΔΗΣ ΘΕΤΙΚΕΣ ΟΡΟΑΝΤΙΔΡΑΣΕΙΣ ΓΙΑ ΣΥΦΙΛΗ, ACQUIRED COAGULATION INHIBITOR, Antinuclear antibodies, BFP-STS, DRUG-INDUCED LUPUS-LIKE SYNDROMES, OBSTETRICAL COMPLICATIONS, THE LUPUS ANTICOAGULANT, Thrombosis, Ιατρική και Επιστήμες Υγείας, Κλινική Ιατρική, Medical and Health Sciences, Clinical Medicine
Networked Digital Library of Theses and Dissertations